Dermapharm Holding SE

BRIEF

published on 03/28/2024 at 07:35, 7 months 26 days ago

Dermapharm Holding SE Meets All Expectations in Challenging Economic Climate

Pharmaceutical Industry Annual Report 2023 Economic Challenges Dermapharm Holding SE Growth Expectations
PRESS RELEASE

published on 03/28/2024 at 07:30, 7 months 26 days ago

Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges
Dermapharm Holding SE fulfils all expectations in 2023 despite macroeconomic challenges, with revenue up by 10.8% to EUR 1,135.4 million and adjusted EBITDA margin at 27.3%

Pharmaceutical Industry Revenue Growth EBITDA Margin Annual Report Dermapharm Holding SE
BRIEF

published on 03/14/2024 at 07:35, 8 months 9 days ago

Dermapharm Holding SE Achieves Top End of Guidance Range Amid Challenges

Financial Results Revenue Growth Pharmaceuticals Dermapharm Holding SE Healthcare Products
PRESS RELEASE

published on 03/14/2024 at 07:30, 8 months 9 days ago

Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
Dermapharm Holding SE reaches upper end of adjusted EBITDA guidance range by achieving 10.8% revenue growth in 2023, proposes a dividend of EUR 0.88 per share for the year

Financial Results Adjusted EBITDA Revenue Growth Dividend Proposal Dermapharm Holding SE
PRESS RELEASE

published on 08/29/2023 at 07:30, 1 year 2 months ago

Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall
PRESS RELEASE

published on 08/16/2023 at 07:30, 1 year 3 months ago

Dermapharm Holding SE: First half of 2023 is a success despite the challenging market environment
PRESS RELEASE

published on 06/14/2023 at 17:00, 1 year 5 months ago

Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 1.05 per share
PRESS RELEASE

published on 06/13/2023 at 15:15, 1 year 5 months ago

Dermapharm Holding SE invests in family-owned Austrian pharmaceutical company Montavit
PRESS RELEASE

published on 05/15/2023 at 07:30, 1 year 6 months ago

Dermapharm Holding SE: outstanding start to financial year 2023
PRESS RELEASE

published on 03/28/2023 at 07:29, 1 year 7 months ago

Dermapharm Holding SE: Dermapharm Holding SE surpasses one billion in revenue for first time in 2022 and maintains growth trajectory

Published on 11/22/2024 at 23:55, 9 hours 12 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 37 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 10 hours 2 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 10 hours 2 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 37 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 14 hours 52 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 15 hours 7 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 15 hours 14 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 12 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 17 hours 7 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 18 hours 32 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 2 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 13 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News